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We present here environmental factors including pH shifts, temperature, and metal ions surrounding Aβ40 monomer to precede
the oligomers. We also suggest a new idea to detect Aβ40 oligomers with anti-Aβ40 monoclonal antibody using enzyme-linked
immunosorbent assay. This method involves the diﬀerent sensitivity of the thermal shifts between Aβ40 monomer and the
oligomers. The idea is useful for the diagnostics of Alzheimer’s disease to detect Aβ40 oligomers in the serum from the patients.
1.Introduction
Alzheimer’s disease (AD) is the most common of senile
dementia and characterized by memory loss, deterioration
of cognitive and behavioral processes and social life, and
these symptoms showed no relief through the life. The major
pathological hallmark of AD is the accumulated Aβ plaques
in the extracellular liquid [1] and neuroﬁbrillary tangles
in the intracellular accumulation of hyperphosphorylated
and misfolded tau protein [2–4]. Among the brain lesions
that are aﬀected in AD and contain the highest number
of senile plaques are the amygdala [5] and hippocampus
[6]. The amygdala is involved in modulation of behavior,
emotion, and memory due to its vast aﬀerent and eﬀerent
projections. It has been reported that although lesions of
amygdalaalonedonotappeartoimpairspatiallearning,they
potentiate hippocampus lesion-induced disruption of spatial
learning [7]. The Aβ plaques are mainly composed of β-
structured ﬁbrils made up to β-amyloid protein 40/42 amino
acid residues long (Aβ40/42), and they are processed from
amyloid precursor protein (APP) in neurons and secreted
into the interstitial ﬂuid space (IFS) of the brain in the
soluble form [8] and cerebrospinal ﬂuid (CSF) that help to
clear Aβ from IFS to the bloodstream [9, 10].
Some of misfolding mechanisms of Aβ to induce aggre-
gation appear in AD brain. Because the aggregated Aβ is
observed as extracellular structure, the concentration of Aβ
in the ISF [15] and the environmental factors surrounding
the protein may aﬀect the process. Detection of the most
toxic Aβ species to synapse and neuron [16] present during
Aβ aggregation is a critical aspect in AD diagnostics. The
molten-globule state of the protein that is a misfolding
intermediate, Aβ oligomers before Aβ plaque formation is
responsible for neuronal damages [17].
One possible model of direct Aβ cytotoxicity involves
the cytopathic eﬀect of amyloid ﬁbrils, which are rich in
β-sheets and thereby interact with cell surface receptors
and result in aberrant activation of signal transduction
pathways. This model in consistent with the observation
of hyperphosphorylated focal adhesion kinase [18]a n d
microtubule-associated tau protein [19]. Persistent binding
and activation of cellsurfacereceptors byamyloid ﬁbrils may
induce neuronal apoptosis. An alternative possibility of Aβs
cytotoxicity is the direct damages to the cell surface mem-
brane to form pores and induce calcium inﬂux by hydrolytic
activityofAβ40oligomers[20].Recentstudyreportscalcium
ions stimulate the formation of Aβ40 oligomers that causally
implicated in neuronal toxicity of AD [21].2 Journal of Amino Acids
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Figure 1: Environmental factors surrounding Aβ40 to precede Aβ40 oligomers. Aβs are exposed to the variety of environmental factors
that aﬀect the conformational changes. These factors involve pH shift, temperature, metal ions, sounds, gravity, atmospheric pressure, and
vibration. These factors might be responsible to induce soluble Aβ monomer into oligomers which is a component of neurodegenerative
process.
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Figure 2:ReactivitypatternsofantibodiesdiﬀerafterpH-modiﬁcationoftheAβ40peptide[11].ThepH-modiﬁedAβ40peptides(4μg/mL)
at various pH values were tested for monoclonal antibody (e.g., anti-1–7 (fuchsia diamond), anti-5–10 (green square), 6F/3D (yellow circle),
and 4G8 (red triangle)) and anti-1–42 (blue circle) which is a polyclonal antibody, binding at a concentration of 1μg/mL on the standard
ELISA system. Absorbance was measured at 405nm. Results are expressed as means ± SEM (n = 6). The anti-1–7 and anti-5–10 antibodies
showed very similar reactivity towards Aβ40 incubated at various pH values, the reactivity remaining constant over the entire pH range. In
constant, the 6F/3D antibody showed decreasing reactivity as the pH was lowered from pH 8.0 to 4.6, followed by a dramatic increase as the
pH was lowered from pH 4.6 to 3.0. Interestingly, reactivity of the 4G8 antibody showed a proﬁle similar to that shown by antibody 6F/3D,
with the lowest signal at pH 4.6.
Many candidates of AD biomarker in blood, plasma,
serum, and CSF are reported. The CSF levels of Aβ42, tau
andphosphorylatedtauarepotential biomarkersofAD[22],
and plasma measures of Aβ are of limited diagnostic value
but may provide important information as a measure of
treatment response [23].
Many monoclonal antibodies (moAbs) to recognize
Aβ40 monomer are reported, and their epitopes are deter-
mined; however, there is no speciﬁc moAb for Aβ40
oligomers. The conformational changes of Aβ40 monomer
to oligomers are induced in response to physiological envi-
ronments surrounding Aβ40, and some of Aβ40 sequences
are responsible to the changes. We used the moAb to react
with the responsible sequence to the changes.
The Aβ40 monomer is ﬂexible and have high free energy
before exposure to environmental changes, and the moAb
shows high level of signals; however, after the exposure, its
ﬂexibility is constricted and free energy became low. In theJournal of Amino Acids 3
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Figure 3: Aﬃnity of moAbs to pH-modiﬁed PrP(23–231) and PrP(90–231) [12]. The pH dependence of the aﬃnity of rFab 13A5 (fuchsia
square), mAb 6H4 (green diamond), and mAb MAI–750 (yellow triangle) toward (a) SHaPrP(29–231) and (b) SHaPrP(90–231) after
incubation at various pH values within the range 3.0–7.2 was tested. Four acidic residues are clustered in the central region within the
nine residues 144–152, and rFab 13A5, mAb 6H4, and mAb MAI–750 could bind in this region. None of these antibodies showed any pH
dependence of reactivity toward PrP(29–231), whereas MAI-750 showed a pH dependence around at pH 4 to 5 in its reactivity toward
PrP(90–231). A further reduction in the reactivity of MAI-750 at very low pH suggests that the antibody is unable to bind to its epitope
when the acidic groups are strongly protonated.
steps, some epitopes of the moAb are hidden inside the
oligomers and the moAb could not bind to the epitopes,
which resulted in the low level of signals. The remarkable fall
downofreactivityofmoAbtowardsAβ40monomerisuseful
to distinguish from Aβ40 oligomers, because the reactivity
towards Aβ40 oligomers show no changes before and after
the exposure. We applied the idea to determine Aβ40 forms
in Alzheimer’s disease patients serum.
2.EnvironmentalFactorsSurroundingAβ40
Aβs on the neuronal cell are exposed to various intracel-
lular, and extracellular environmental factors in brain. Aβs
are exposed to acidic pH in lysosome and extracellular
factors surrounding Aβs involve temperature, metal ions,
vibration, sounds, gravity, pressure, free radicals, lipid,
concentration, and chemical chaperones [24]. These factors
might be responsible to induce soluble Aβ monomers to
molten-globule states of oligomers which are a component
of neurodegenerative process and toxic to neuronal cells
(Figure 1).
2.1. pH Shifts. T h en a t i v ec o n f o r m a t i o no fA β in AD and
PrP in Scrapie is modulated by pH shift surrounding the
protein, resulting in a “molten globule” state that is less
ordered than native protein and is a folding intermediate
to precede amyloid protein, however, still preserve the mean
overall feature of the native protein [25].
In Aβ40, a critical pH to induce the conformational
transition is at around pH 5, which is a mimicking of a
lysozomalpH[11].TheresponsiblesequencestothepHshift
was Aβ 9-14:GYEVHH and 17–21:LVFFA, and the Glu at
position 11 is most responsible to the acidic pH shift and
induce soluble Aβ40 to insoluble form [26]( Figure 2).
Scrapie is a disease of protein misfolding of cellular
prion protein (PrPc), in which the largely α-helical and PrPc
is converted to pathological isoform of scrapie PrP(PrPsc),
that is rich in β-sheet [27, 28]. PrPsc is formed in caveolae4 Journal of Amino Acids
and subsequently accumulated in endosomes and secondary
lysosomes where the pH falls down to around pH 4-5 [29].
A proteolytically truncated form of PrPcs corresponding to
PrP(90–231)retainsinfectivityandformamyloidﬁbrils[30],
and truncated PrPc(PrP90–231) with the same amino acid
sequence can be converted to PrPsc in both cultured cells and
transgenic mouse [31].
The pH dependence of PrP(90–231) was tested, and
the moAbs which recognize amino acids sequence of 94–
105(GTHNQWNKPSKP), 107–112(TNMKHM), and 138–
142(MMHFG) of PrPc showed pH-dependent reactivity.
They showed high signals towards PrP(90–231) modiﬁed
below pH 4.7, and the signals fall down remarkably towards
PrP(90–231) modiﬁed over pH 5.2, suggesting that these
regions of PrP(90–231) were sensitive to pH shifts; however,
the signals from the same region of the full length of PrP(29–
231) showed no sensitivity to the entire pH shifts. This
pH dependence of PrP(90–231) suggests the titration of an
acidic region that might inhibit the N-terminal epitopes. A
similar pH dependence for a monoclonal antibody reactive
to the central region of 146–154(EDRYYRENM) identiﬁed
an acidic region incorporating Glu152 as a signiﬁcant
participant (Figure 3)[ 12].
2.2. Temperature within Physiological Limits. Temperature-
induced transition of Aβ40 plays an important role in the
structural transformation from α-helix and random coil to
β-sheet form in aqueous solution by heating [32]. High
temperature induces structural changes in Aβ (tangle and
plaques) or changes in brain similar to those observed in AD
[33]. The conformation of Aβ40 at 0–20◦Cw a sα-helical,
whereas conformational changes of Aβ40 towards β-sheet
conformation were observed at between 35–45, 60–65, and
80–85◦C[ 13].
The occurrence of changes within speciﬁc temperature
ranges may indicate thermal speciﬁcity or adoption by Aβ40
of various conformations at wide range of heating, due
to increasing intermolecular β-sheet structures [34]. The
temperature within the physiological limits also induced the
changes to Aβ40, the apparent changes were observed at 36–
38◦C in the amino acid residues 9–14, and the changes in the
amino acid residues 17–21 were observed at 36–40◦C[ 13],
andbothsequenceshavebeenreportedtobeinvolved inpH-
induced conformational transition of Aβ40 [11]( Figure 4).
The observation within physiological limits may occur in
vivo with high fever over 38◦C in response to inﬂammatory
disease, and thermal stress may aﬀect Aβ40 in our brain.
Temperature-dependent secondary structure of Aβ40,
Aβ42 and Aβ28 in the solid state was also studied by
simultaneous Fourier transform infrared/diﬀerential scan-
ning calorimetry (FT-IR/DSC) microspectroscopic system.
Basically, Aβ28 is composed from major β-sheet and minor
α-helix with little random coil, and Aβ40 consisted of
major β-sheet, minor random coil, and little α-helix, but
Aβ42mainlyconsistedofthepredominantβ-sheetstructure.
Thus, the intact Aβs show a diﬀerent secondary structures,
and thermal treatment induces a similar β-sheet structure
for Aβ40 at 45◦Ca n df o rA β28 at 40◦C; however, there
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Figure 4: Aﬃnity of moAbs to thermal-modiﬁed Aβ40 [13].
Enzyme-linked immunosorbent assay (ELISA) measurements of
antibody aﬃnity towards temperature-modiﬁed Aβ40 were per-
formed. The reactivity of four antibodies as mentioned in Figure 2
(4G8, 6F/3D, anti-1–7, anti-5–10) to samples of Aβ40 that had been
exposed to temperatures over the range 36–42◦Ca t1 ◦C interval
and at 20◦C as a control, was monitored by ELISA. Statistical
comparisons were performed with unpaired t-tests. The values are
means ± SEM. Statistically signiﬁcant diﬀerences versus 6F/3D
w e r ed e t e r m i n e da te a c ht e m p e r a t u r e( n = 6). For both anti-
5–10 and 1–7 antibodies, the reactivity was constant through the
whole temperature range from 35◦Ct o4 2 ◦C, and no temperature-
dependent diﬀerence was detected. The monoclonal antibody
6F/3D showed temperature-dependent reactivity, and the reactivity
was bimodal, when the modiﬁed temperature was increased from
36 to 38◦C and from 38 to 41◦C. On the other hand, 4G8 showed
temperature-dependent reactivity, when the temperature increased
from 36 to 40◦C. Thus, the 9–14 and 17–21 amino acid residues
within Aβ40 peptide were sensitive to temperature changes.
was no transitional temperature for Aβ42 [35]. Actually,
temperature at 45◦C induced changes for Aβ40 by reducing
the compositions from 37 to 20–24% for α-helical and
random coil structures but increasing the components from
27 to 45% for intermolecular β-sheet structures [34]. The
thermal-induced denaturation is an important factor in the
structural transformation from α-helix/random coil to β-
sheet in Aβs.
2.3. Metal Ions. The metal ions such as Zn2+,C u 2+ were
implicated in AD progression [36–38], and their interaction
with Aβ in stimulating Aβ aggregation has been studied in
vitro. The binding of metal ions induces Aβ conformation,
initially rich in random coil structure to a β-sheet structure,
favorable the partially folding intermediates. Under acidic
pH, Cu2+,a n dF e 3+ induce drastic aggregation; however,
underneutraloralkalinepH,theyshowedlimitedpropensity
to Aβ aggregation [39–41]. Oligomerization of the Aβ
peptides can be rapidly induced in the presence of Zn2+ ions
under physiological conditions [42–44], and, under both at
alkaline and acidic pH, it could induce Aβ aggregation and
form protease resistant aggregates [45]. It was suggested thatJournal of Amino Acids 5
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Figure 5: Identiﬁcation of response of temperature-modiﬁed serum of patients with Alzheimer’s disease [14]. According to the criteria of
National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders, AD patients were
enrolled, and the patients were classiﬁed into two groups of mild AD and severe AD with age match. MMSE score 1–9 was as severe AD and
the score of 10–22 was as mild AD. Sera from two AD groups were tested for their reactivity against 4G8 with ELISA. (a) The absorbance in
the severe AD was lower than that of the mild AD though the temperatures and the signals from mild AD were almost constant; however,
the signiﬁcant lower signal was observed in severe AD at 40◦C( P<0.02) and 41◦C( P<0.05). The signals from Aβ40 peptide as a control
showed decrease as the temperature increase in a temperature-dependent manner. (b) The minimum/maximum optical density ratio of
each patient’s serum was calculated and obtained the average of ratios for severe and mild AD. The ratio value for patients with severe AD
(0.43 ± 0.05) was signiﬁcantly (P<0.001) lower than that for patients with mild AD (0.69 ± 0.01). The average min/max optical density
value for the synthetic Aβ1–40 peptide, used as a control, was 0.72 ±0.02.
AβpossessespreferentialZn2+-bindingsitesinitsN-terminal
1–16 and the metal ion interacts with His-6, -13, and -
14 both at acidic and alkaline pH [46–48]. Recent reports
suggests that soluble Aβ oligomers rather than matured Aβ
ﬁbrills exhibit the major neurotoxicity and these histidine
residues may be a target to decrease the cytotoxicity [49]a n d
suggested that a Pt compounds and Ru2+ complex may react
with Aβ28 [50].
Recent report suggest the mechanisms and structures
of amyloid formation by Zn2+ binding. Though Zn2+ does
not aﬀect the β-sheet association around the C-terminal
hydrophobic region, it shifts the relative aggregation major
species. As a result, Zn2+ coordination promotes Aβ42
aggregation leading to less uniform structures and increasing
Zn2+ concentration slows down the aggregation rate [51].
Though there are many reports to demonstrate the
neurotoxic eﬀects and their interference with a variety of
cellular and metabolic process, the pathogenesis of Al3+ in
AD is still under debate [52, 53]. A comparative study under
alkaline pH showed that Zn2+ and Cu2+ ions were much less
eﬃcient than Al3+ ion in stimulating the spontaneous ﬁbril
formation of Aβs. The putative Al3+-chelating amino acid
residues are present both in the hydrophilic segment (Aβ1–
16) and in the hydrophobic core (Aβ20–35), suggesting that
the Al3+-binding is less restricted than that for Zn2+ and
Cu2+, which is conﬁned to the N-terminal sequence [54].
3. Application of Temperature-Induced
Aβ40 Conformational Changes for AD
Diagnostics[14]
The earlier intervention is required in AD treatments, and
the determination of clinical phase of AD in early stage
is necessary. Up to date, there are no reports about useful
markers of AD staging.
We exposed Aβ40 peptide to the thermal shifts and
observed the reactivity pattern to moAbs with an enzyme-
linked immunosorbent assay (ELISA) before and after the6 Journal of Amino Acids
exposures. The signals from Aβ40 before thermal exposure
fall down after the exposure, in which Aβ40 oligomerization
is induced by thermal shifts.
The clinical phase of AD was determined with MMSE,
and mild AD presents MMSE over 24 and severe AD
presents MMSE below 9. We used the sera from patients
diagnosedwithmildADandsevereADtodetectthediﬀerent
reactivity pattern to speciﬁc antibodies targeting Aβ17–
21(4G8 moAb). The reactivity patterns of sera to 4G8 at
36–42◦C was determined by ELISA. The Aβ40 peptide as
a control showed the reactivity pattern in a temperature-
dependent manner, and the reactivity of sera from patients
with severe AD was less than that of sera from patients
with mild AD though the temperatures 36–41◦C and the
remarkable fall down at 41-42◦C were shown in severe
AD, however, with no diﬀerence at 42◦C( Figure 5(a)). The
severity of AD is associated with greater Aβ40 aggregation.
WeproposethattheratioofdiﬀerencesofsignalswithELISA
between 38◦Ca n d4 0 ◦C is useful to determine the severity
of AD (Figure 5(b)). The present results may be of value in
staging and following up of patients with AD.
4. Conclusion
Acidic environment at around pH 5, a temperature between
38-39◦C within physiological limits, and Cu2+ and Zn2+
ion at neutral pH could precede Aβ40 from monomer to
oligomers. The sequence of QKLVFFA is responsible of the
changes, and it is crucial of Aβ oligomerization, and the
sequence may be useful as a biomarker of Aβ40 oligomers
in AD serum. The diﬀerences of Aβ40 conformation in AD
patients serum were demonstrated as the diﬀerent sensitivity
of Aβ40 in response to the thermal shift, and it was detected
with the moAb which recognizes QKLVFFA, corresponding
to amino acids 15–21 of Aβ40/42 by ELISA. We suggest here
a new diagnostic approach for AD staging by monitoring
the reactivity mode of the moAb to Aβ40 before and after
exposure to the thermal shift.
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